Small-Molecule Inhibitors and Agonists in Cancer Research

Researchers investigating cancer-related signaling pathways often face a recurring obstacle: tool compounds that vary between batches, lack cell permeability, or require transfection agents that complicate experimental design. 

• Why Signaling Pathway Tool Compounds Matter

Cancer-related signaling pathway research depends on compounds that deliver high purity with clear chemical composition, verified through HPLC, NMR, and LC/MS testing. This verification process directly supports two practical needs in the lab: stable, low batch-to-batch variation for repeated studies, and informative dose-response data because dose can be easily manipulated. Equally important, these compounds are cell-permeable without transfection agents, which simplifies experimental workflow by removing an extra variable from the protocol. Collectively, these features allow compounds to act by inhibiting or inactivating specific targets within pathways that are central to cancer biology.

• Coverage Across Key Cancer-Related Pathways

TargetMol, a global leading life science reagents and services supplier, addresses this gap with a catalog of 100,000+ inhibitors & agonists designed to bind targets such as proteins, genes, or RNA and reduce their biological activity in a controlled, reproducible manner. TargetMol organizes its catalog around major signaling pathway categories relevant to oncology research, each populated with well-characterized compounds and their associated targets, development conditions, and indications.

Angiogenesis and Receptor Tyrosine Kinase Signaling —This category includes compounds targeting EGFR, FGFR, VEGFR, PDGFR, c-Kit, and Bcr-Abl. Examples include Afatinib (ID T21312, CAS 850140-72-6), marketed and in Phase 1 for non-small-cell lung cancer; Pemigatinib (ID T12401, CAS 1513857-77-6), marketed and in Phase 3 for cholangiocarcinoma and related indications; and Erdafitinib (ID T3726, CAS 1346242-81-6), marketed and in Phase 3 across multiple solid tumor indications. Imatinib (ID T6230, CAS 152459-95-5) and Asciminib (ID T5177, CAS 1492952-76-7) represent marketed Bcr-Abl-directed options for chronic myeloid leukaemia.

Apoptosis Pathway Modulators  — Compounds here act on p53, Mdm2, BCL, Caspase, and RIP kinase targets. Thalidomide (ID T0213, CAS 50-35-1) and Ixazomib (ID T2122, CAS 1072833-77-2) are marketed, Phase 4 compounds relevant to multiple myeloma research. Docetaxel trihydrate (ID T0186, CAS 148408-66-6) targets Apoptosis, BCL, and Microtubule Associated pathways and is marketed across Phase 3 indications including breast and non-small-cell lung cancer.

Cell Cycle & Checkpoint Regulation  — This set targets Aurora Kinase, Chk, and CDK, supporting studies on cell division control. Ribociclib succinate (ID T15732, CAS 1374639-75-4) is marketed and in Phase 3 for advanced breast cancer, while AZD4573 (ID T10436, CAS 2057509-72-3) is in Phase 1/2 across a range of haematological malignancies.

Chromatin & Epigenetic Targets  — Compounds act on Epigenetic Reader Domain, Histone Acetyltransferase, Histone Demethylase, and Histone Methyltransferase proteins. Tazemetostat hydrobromide (ID T17002, CAS 1467052-75-0) is a marketed Histone Methyltransferase-directed compound indicated for follicular lymphoma and sarcoma, while ABBV-744 (ID T4697, CAS 2138861-99-9) is in Phase 1/Preclinical stages for acute myeloid leukaemia and prostate cancer.

MAPK Signaling  — This category covers ERK, MEK, Raf, p38 MAPK, and JNK targets. Binimetinib (ID T2508, CAS 606143-89-9) is marketed and in Phase 3 for colorectal, fallopian tube, ovarian, peritoneal cancer, and malignant melanoma. Sorafenib (ID T0093L, CAS 284461-73-0) and its tosylate form target Raf, VEGFR, PDGFR, and c-Kit, with marketed status for hepatocellular carcinoma, liver cancer, renal cell carcinoma, and thyroid cancer.

PI3K, Akt & mTOR Signaling — Compounds target PI3K, Akt, mTOR, AMPK, and GSK-3. Copanlisib dihydrochloride (ID T14998, CAS 1402152-13-9) is marketed and in Phase 3 for B-cell lymphomas, and Everolimus (ID T1784, CAS 159351-69-6) is marketed and Phase 4 across numerous indications including renal cell carcinoma and liver cancer.

NF-κB and Ubiquitination Pathways —  These sections include IκB/IKK, NF-κB, Proteasome, and DUB-targeting compounds such as Sulfasalazine (ID T0907, CAS 599-79-1) and Pevonedistat (ID T6332, CAS 905579-51-3), the latter in Phase 3/Preclinical stages for acute myeloid leukaemia and several other malignancies.

Tyrosine Kinase & Adaptor Proteins  — Compounds targeting c-Met/HGFR, ALK, c-Kit, c-RET, and FLT support studies on receptor tyrosine kinase-driven cancers. Crizotinib hydrochloride (ID T8399, CAS 1415560-69-8) is marketed and Phase 4 for locally advanced or metastatic non-small cell lung cancer, and Selpercatinib (ID T8222, CAS 2152628-33-4) is marketed and Phase 3 for medullary thyroid cancer and related indications.

• Quality Assurance Behind Every Compound

Every product line benefits from TargetMol’s Technology Platform, which combines CADD (computer-aided drug design), chemical synthesis, and a quality verification platform using HPLC, NMR, and LC/MS tests. This infrastructure underlies the 100,000+ inhibitors & agonists, 1,000+ compound library types, 20,000+ natural products, and 8,000+ peptides  and more available in the catalog, giving researchers access to a broad set of tools within a single supplier relationship.

• Supporting Custom Research Needs

When catalog products do not meet a specific experimental requirement, TargetMol’s Chemical Synthesis & Customization service addresses this through in-house synthesis capability, allowing researchers to request client-specific compounds rather than relying solely on stock offerings.

• Global Reach and Research Recognition

TargetMol serves clients in 60+ countries and 8,000+ organizations, operating from offices in Wellesley Hills, MA, USA, Linz, Austria, and Shanghai, China. The company’s products have been cited in peer-reviewed literature, appearing in Nature (Volume 368, Issue 6497, and Volume 582, Issue 7811) in 2020, and across Cancer Cell, Cell, Immunity, Cell Research, Cancer Discovery, Gastroenterology, and Journal of Medical Virology between 2020 and 2022, contributing to a total of 15,000+ Citations. In 2023, the company received an award for a fast increase in the number of citations and was named Winner, TargetMol Biochemical Supplier to Watch in 2023. More recently, TargetMol was recognized as the 2025 Bioz Rising Star Award Winner in the Inhibitor products catalog.

For in-stock products, TargetMol maintains 1-2 day delivery, backed by a fast and efficient global supply chain and professional technical support across US, Europe, and Asia-Pacifics. This combination of broad catalog depth, verified quality, custom synthesis capability, and responsive delivery positions TargetMol as a resource for researchers studying cancer-related signaling pathways who need dependable tool compounds across angiogenesis, apoptosis, cell cycle, epigenetic, MAPK, PI3K/Akt/mTOR, NF-κB, tyrosine kinase, and ubiquitination research domains. 

Explore more: https://www.targetmol.com/ 

http://www.targetmol.com
TargetMol Chemicals Inc.